The
global Intravenous
Immunoglobulin Market size is expected to reach USD 21.05 billion by
2030, registering a CAGR of 7.3% over the forecast period, according to a new
report by Grand View Research, Inc. The increasing prevalence of
immunodeficiency diseases, coupled with the adoption of intravenous
immunoglobulin (IVIG) therapies, is expected to fuel market growth over the
forecast period. In addition, increasing off-label use of immunoglobulin and
investments in the healthcare sector are factors propelling the market growth. Moreover,
increasing incidences of bleeding disorders and the growing geriatric
population are the factors contributing to the industry growth.
The
rising incorporation of subcutaneous immunoglobulin in the treatment of primary
immunodeficiency diseases as well as in replacement therapy is anticipated to
provide a growth platform to the market in the next seven years. Moreover,
the key market players are focusing on breakthrough product introductions
to expand their global distribution network. For instance, Octapharma
U.S. got FDA clearance in July 2021 for Octagam 10%, its first intravenous
immunoglobulin recommended for the treatment of the immune-mediated
inflammatory illness known as dermatomyositis in adults.
The
COVID-19 pandemic, which is currently in its last stages, is expected to boost
the worldwide market for intravenous immunoglobulin. In India, for instance,
Bharat Biotech is conducting a study to create monoclonal antibodies as a
potential COVID-19 treatment. The Council of Scientific and Industrial Research
(CSIR) has approved the project as part of its New Millennium Indian Technology
Leadership strategy. Moreover, COVID-19 has caused substantial issues for
patients with mental and neurological disorders due to their increased
susceptibility to infection. For instance, in April 2021, Grifols, a
key provider of plasma-derived medicines, contributed to a research study
in collaboration with both the NIH and NIAID, to analyze an intravenous
anti-SARS-CoV-2 hyperimmune globulin among outpatients. This is expected to
provide a boost to the market growth in the forecast period.
Key
players are adopting strategic alliances to sustain the competition. These
initiatives include mergers & acquisitions, collaborations, and new product
developments. For instance, in March 2022, Grifols' XEMBIFY has been approved
in Europe, increasing access to novel medicines. Grifols' clearance in Europe
allows it to extend its breakthrough European IG product range and offer
patients and healthcare professionals another crucial therapy solution for
primary and secondary immunodeficiencies. In February 2021, Pfizer gained US
FDA clearance for the supplemental Biologics License Application (sBLA) with
PANZYGA, an intravenous immunoglobulin to cure adult patients with severe
inflammatory demyelinating polyneuropathy (CIDP).
List of Key Players in the Intravenous Immunoglobulin
Market
- Biotest AG
- Baxter
International Inc.
- Octapharma
AG
- LFB
Biotechnologies
- Grifols SA
- CSL Behring
- China
Biologics Products Inc.
- Kedrion
Biopharma
- BDI Pharma
Inc.
Related Press
Release @ Intravenous
Immunoglobulin Market Report
Intravenous Immunoglobulin Market Report Highlights
- The
hypogammaglobulinemia application segment held the third-largest revenue
share in 2022. This can be attributed to the increasing demand for
immunoglobulin replacement therapies to treat hypogammaglobulinemia
diseases, which is driven by rising awareness levels amongst patients and
increasing incidences of the disease
- The hospital
pharmacy distribution channel segment dominated the market with a revenue
share of over 57.83% in 2022 owing to the large network of hospitals and
the convenient range of products that are easily accessible through
hospital pharmacies. Furthermore, hospitals offer fast reimbursement,
treatment, and proper care to a large number of patients, enabling a surge
in the prevalence of patients selecting hospital pharmacies
- The
specialty pharmacy distribution channel segment is anticipated to expand
at a lucrative CAGR during the forecast period as specialty pharmacies
enable easy treatment at home
- North
America held the largest share of 46.51% in terms of revenue in 2022 due
to the presence of a well-regulated healthcare system, the larger pool of
target population, and high patient awareness pertinent to the plasma
protein products
- Asia Pacific
is expected to register a significant CAGR of 8.4% over the forecast
period owing to the increasing number of patients with bleeding disorders
and the growing number of CIDP patients
- Countries
such as India, China, and South Africa are expected to witness significant
growth over the forecast period owing to improving healthcare facilities,
rising healthcare expenditure, and growing public awareness regarding
immune deficiency disorders
- The Kawasaki
disease application segment is expected to expand at a lucrative CAGR of
9.6% from 2023 to 2030 owing to the massive adoption of IVIG treatment in
the aforementioned disease management
Intravenous Immunoglobulin Market
Report Scope
|
Report Attribute |
Details |
|
Market
size value in 2023 |
USD 12.89
billion |
|
Revenue
forecast in 2030 |
USD 21.05
billion |
|
Growth
rate |
CAGR of
7.3 % from 2023 to 2030 |
|
Base year
for estimation |
2022 |
Request a Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/2692/rfc
Intravenous Immunoglobulin Market Segmentation
Grand
View Research has segmented the global intravenous immunoglobulin market on the
basis of application, distribution channel, and region:
IVIG Application Outlook (Revenue, USD Million, 2018 -
2030)
- Hypogammaglobulinemia
- CIPD
- Immunodeficiency
Diseases
- Congenital
AIDS
- Chronic
Lymphocytic Leukemia
- Myasthenia
Gravis
- Multifocal
Motor Neuropathy
- ITP
- Kawasaki
Disease
- Guillain-barre
Syndrome
- Others
IVIG Distribution Channel Outlook (Revenue, USD Million,
2018 - 2030)
- Hospital
Pharmacy
- Specialty
Pharmacy
- Others
IVIG Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment